Search Results - "Tatli, A.M."

235P The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC) by Artac, M., Cağlayan, D., Koçak, M.Z., Geredeli, C., Tatli, A.M., Sezgin Goksu, S., Karakurt Ery lmaz, M., Araz, M.

Get full text

Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen by Tatli, A M, Uysal, M, Goksu, S S, Gunduz, S, Arslan, D, Ozdogan, M

“…Primary adenocarcinoma of the bladder is a very rare disease that is difficult to treat. In this paper, we report the second case in the literature with…”
Get more information

Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? by Kilickap, S., Buğdaycı Başal, F., Demirkazik, A., Gursoy, P., Demirci, U., Erman, M., Yumuk, F., Cay Senler, F., Cakar, B., Cicin, I., Ozturk, A., Coskun, H.S., Çubukçu, E., Işıkdoğan, A., Olmez, O.F., Tatlı, A.M., Karaagac, M., Şakalar, T., Eralp, Y., Korkmaz, T.

Get full text

1547P - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? by Kilickap, S., Buğdaycı Başal, F., Demirkazik, A., Gursoy, P., Demirci, U., Erman, M., Yumuk, F., Cay Senler, F., Cakar, B., Cicin, I., Ozturk, A., Coskun, H.S., Çubukçu, E., Işıkdoğan, A., Olmez, O.F., Tatlı, A.M., Karaagac, M., Şakalar, T., Eralp, Y., Korkmaz, T.

“…ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we…”
Get full text

The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey by Kilickap, S., Ölmez, ÖF., Cicin, I., Demirci, U., Alan, O., Cabuk, D., Şakalar, T., Tatlı, A.M., Başol Buğdaycı, F., Eralp, Y., Uysal, M., Demirkazık, A., Bilgin, B., Yıldız, B., Karaağaç, M., Okutur, K., Sakin, A.

Get full text